Literature DB >> 28507105

Reduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated Infection.

Sean B Sullivan1, Eloise D Austin1, Stephania Stump1, Barun Mathema2, Susan Whittier3, Franklin D Lowy1,3, Anne-Catrin Uhlemann4.   

Abstract

Methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSIs) often lead to severe complications despite the availability of effective antibiotics. It remains unclear whether elevated vancomycin MICs are associated with worse outcomes. We conducted a 2-year retrospective cohort study (n = 252) of patients with MSSA BSIs at a tertiary care hospital. We defined reduced vancomycin susceptibility (RVS) as a Microscan MIC of 2 mg/liter. All strains were genotyped (spa) and assessed for agr functionality. Multivariable logistic regression models were used to examine the impact of RVS phenotype and strain genotype on 30-day all-cause mortality and complicated bacteremia (metastatic spread, endovascular infection, or duration ≥3 days). One-third of patients (84/252) were infected with RVS isolates. RVS Infections were more frequently associated with metastatic or embolic sites of infection (36% versus 17%, P < 0.001), and endovascular infection (26% versus 12%, P = 0.004). These infections occurred more often in patients with fewer underlying comorbidities (Charlson comorbidity index of ≥3 [73% versus 88%, P = 0.002]). Genotyping identified 127 spa-types and 14 Spa-clonal complexes (Spa-CCs). Spa-CC002 and Spa-CC008 were more likely to exhibit the RVS phenotype versus other Spa-CCs (OR = 2.2, P < 0.01). The RVS phenotype was not significantly associated with 30-day mortality; however, it was associated with complicated bacteremia (adjusted odds ratio of 2.35 [range, 1.26 to 4.37]; P = 0.007) in adjusted analyses. The association of RVS strains with complicated infection and fewer underlying comorbidities suggests the phenotype as a potential marker of strain virulence in MSSA BSIs. The RVS phenotype itself was not a significant predictor of mortality in this patient cohort. Further studies are necessary to explore this host-pathogen relationship.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  MSSA bacteremia; reduced vancomycin susceptibility

Mesh:

Substances:

Year:  2017        PMID: 28507105      PMCID: PMC5487643          DOI: 10.1128/AAC.00316-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management.

Authors:  Dag Harmsen; Heike Claus; Wolfgang Witte; Jörg Rothgänger; Hermann Claus; Doris Turnwald; Ulrich Vogel
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia.

Authors:  Yoshio Takesue; Kazuhiko Nakajima; Yoshiko Takahashi; Kaori Ichiki; Mika Ishihara; Yasunao Wada; Toshie Tsuchida; Motoi Uchino; Hiroki Ikeuchi
Journal:  J Infect Chemother       Date:  2010-07-13       Impact factor: 2.211

3.  Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre System and the MicroScan System. Comparison with results from the conventional Etest and CLSI standardized MIC methods.

Authors:  Rohan Nadarajah; Linda R Post; Catherine Liu; Steven A Miller; Daniel F Sahm; Geo F Brooks
Journal:  Am J Clin Pathol       Date:  2010-06       Impact factor: 2.493

4.  Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.

Authors:  Sanjiv M Baxi; Angelo Clemenzi-Allen; Alice Gahbauer; Daniel Deck; Brandon Imp; Eric Vittinghoff; Henry F Chambers; Sarah Doernberg
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

5.  Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus.

Authors:  Simone Shurland; Min Zhan; Douglas D Bradham; Mary-Claire Roghmann
Journal:  Infect Control Hosp Epidemiol       Date:  2007-02-15       Impact factor: 3.254

6.  Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.

Authors:  N E Holmes; J D Turnidge; W J Munckhof; J O Robinson; T M Korman; M V N O'Sullivan; T L Anderson; S A Roberts; S J C Warren; W Gao; P D R Johnson; B P Howden
Journal:  Clin Microbiol Infect       Date:  2013-02-26       Impact factor: 8.067

7.  Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.

Authors:  Satish K Pillai; Christine Wennersten; Lata Venkataraman; George M Eliopoulos; Robert C Moellering; Adolf W Karchmer
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

8.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy.

Authors:  J W Chow; M J Fine; D M Shlaes; J P Quinn; D C Hooper; M P Johnson; R Ramphal; M M Wagener; D K Miyashiro; V L Yu
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

Review 9.  The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.

Authors:  Benjamin P Howden; Anton Y Peleg; Timothy P Stinear
Journal:  Infect Genet Evol       Date:  2013-04-06       Impact factor: 3.342

10.  High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Jose Maria Aguado; Rafael San-Juan; Antonio Lalueza; Francisca Sanz; Joaquin Rodríguez-Otero; Carmen Gómez-Gonzalez; Fernando Chaves
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

View more
  13 in total

1.  Reduced Mortality of Staphylococcus aureus Bacteremia in a Retrospective Cohort Study of 2139 Patients: 2007-2015.

Authors:  Eloise D Austin; Sean S Sullivan; Nenad Macesic; Monica Mehta; Benjamin A Miko; Saman Nematollahi; Qiuhu Shi; Franklin D Lowy; Anne-Catrin Uhlemann
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

2.  Association of Vancomycin MIC and Molecular Characteristics with Clinical Outcomes in Methicillin-Susceptible Staphylococcus aureus Acute Hematogenous Osteoarticular Infections in Children.

Authors:  Eric Y Kok; Jesus G Vallejo; Lauren M Sommer; Louie Rosas; Sheldon L Kaplan; Kristina G Hulten; J Chase McNeil
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.

Authors:  Rocío Falcón; Eva Mateo; Rosa Oltra; Estela Giménez; Eliseo Albert; Ignacio Torres; David Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-06       Impact factor: 3.267

4.  Molecular characterization of Staphylococcus aureus isolated from hospital acquired sepsis in pediatrics, relation to antibiotics, resistance and virulence genes.

Authors:  Maysaa Zaki; Sara Galeb; Abdel-Rahman Eid; Doaa Ahmed; Amna Mabrouk; Radwa Abdel Latif
Journal:  Germs       Date:  2020-12-28

5.  Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia.

Authors:  Natasha E Holmes; J Owen Robinson; Sebastiaan J van Hal; Wendy J Munckhof; Eugene Athan; Tony M Korman; Allen C Cheng; John D Turnidge; Paul D R Johnson; Benjamin P Howden
Journal:  BMC Infect Dis       Date:  2018-03-05       Impact factor: 3.090

6.  Reduced Vancomycin Susceptibility, MRSA and Treatment Failure in Pediatric Staphylococcus aureus Bloodstream Infections.

Authors:  Ethan Canty; Benjamin Carnahan; Tara Curley; Emily Anususinha; Rana F Hamdy; Jessica E Ericson
Journal:  Pediatr Infect Dis J       Date:  2021-05-01       Impact factor: 2.129

7.  Antimicrobial activity of apple cider vinegar against Escherichia coli, Staphylococcus aureus and Candida albicans; downregulating cytokine and microbial protein expression.

Authors:  Darshna Yagnik; Vlad Serafin; Ajit J Shah
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

8.  Staphylococcus aureus bacteremia in a secondary level Spanish hospital: clinical implications of high vancomycin MIC.

Authors:  G Abelenda Alonso; M D Corbacho Loarte; R Núñez Ramos; M Cervero Jiménez; J J Jusdado Ruiz-Capillas
Journal:  Rev Esp Quimioter       Date:  2018-05-04       Impact factor: 1.553

9.  The Cefazolin Inoculum Effect and the Presence of type A blaZ Gene according to agr Genotype in Methicillin-Susceptible Staphylococcus aureus Bacteremia.

Authors:  Soon Ok Lee; Shinwon Lee; Sohee Park; Jeong Eun Lee; Sun Hee Lee
Journal:  Infect Chemother       Date:  2019-12

10.  Dysfunctional accessory gene regulator (agr) as a prognostic factor in invasive Staphylococcus aureus infection: a systematic review and meta-analysis.

Authors:  Soon Ok Lee; Shinwon Lee; Jeong Eun Lee; Kyoung-Ho Song; Chang Kyung Kang; Yu Mi Wi; Rafael San-Juan; Luis E López-Cortés; Alicia Lacoma; Cristina Prat; Hee-Chang Jang; Eu Suk Kim; Hong Bin Kim; Sun Hee Lee
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.